Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05624268 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
A Phase 3 study of Treatment-Resistant Depression, sponsored by COMPASS Pathways.
- Active
- Registry status
- Phase 3
- Development phase
- 255
- Enrollment target
- 20
- Study locations
NCT05624268 is a Phase 3 study of Treatment-Resistant Depression that is active but no longer recruiting, run by COMPASS Pathways. The registered enrollment target is 255 participants, below the 369-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05624268, a Phase 3 study of Treatment-Resistant Depression, is active but no longer recruiting, sponsored by COMPASS Pathways.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 255 participants
- Enrollment target
- 20
- Study locations
Study Summary
Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
Conditions Studied
Interventions
- DRUG Psilocybin
Study Locations (20)
California
- ProScience Research Group - Culver City
- Collaborative Neuroscience Network, LLC - Garden Grove
- Kadima Neuropsychiatry Institute - La Jolla
- University California San Diego - La Jolla
- California Center for Psychedelic Therapy - Los Angeles
- CalNeuro Research Group, Inc - Los Angeles
- Clarity Clinical Research, LLC - Los Angeles
- ATP Clinical Research, Inc. - Orange
- Artemis Institute for Clinical Research - San Diego
- Lumos Clinical Research Center - San Jose
- Stanford University - Stanford
- ASCLEPES Research Centers - Thousand Oaks
Florida
- Clinical Neurosciecne Solutions, Inc. dba CNS Healthcare - Orlando
- APG Research, LLC - Orlando
- DMI Health Care Group, Inc - Tampa
- Meridien Research/Accel Research - Tampa
Georgia
- Psych Atlanta - Atlanta
- Emory University - Atlanta
Arizona
- University of Arizona College of Medicine - Tuscon - Tucson
Connecticut
- Comprehensive Psychiatric Care - Norwich
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2023-01-19 |
| Est. Completion | 2026-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05624268
The ClinicalTrials.gov registry entry for NCT05624268 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 369-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (31% lower). The listed sponsor is COMPASS Pathways, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which Psilocybin is the first listed.
NCT05624268 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05624268 about?
NCT05624268 is a clinical study titled "Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD". Efficacy, Safety, and Tolerability of a single administration of COMP360 in participants with treatment-resistant depression (TRD)
What is the current status of trial NCT05624268?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 255 participants. The study started on 2023-01-19. Estimated completion is 2026-04.
What conditions does trial NCT05624268 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT05624268?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05624268?
This trial is sponsored by COMPASS Pathways, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05624268 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Psilocybin-Assisted Therapy in Treatment-Resistant Depression
RECRUITING · Phase 3
-
Biomarker-guided rTMS for Treatment Resistant Depression
RECRUITING · Phase 3
-
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
ACTIVE NOT RECRUITING · Phase 3
-
A Study in Relapse Prevention of Treatment-Resistant Depression
COMPLETED · Phase 3
-
Open-Label Safety Study of AXS-05 in Subjects With Depression
COMPLETED · Phase 3
-
Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.